On November 22, 2024, Fosun Pharma announced significant progress in its privatization merger plan for Henlius. The offeror received approval from China's National Development and Reform Commission on November 21, 2024, and is in contact with the local authorities of the Ministry of Commerce in China to prepare for the registration with the State Administration of Foreign Exchange. This merger plan will only take effect once all conditions precedent are met and cannot be waived.\nAccording to the announcement on August 23, 2024, the comprehensive documents will be sent within 7 days after the conditions precedent are satisfied or by May 7, 2025, whichever comes first. The offeror, Fosun Pharma, and the company do not guarantee that all conditions precedent will be met, and the merger agreement may...Show More

On November 22, 2024, Fosun Pharma announced significant progress in its privatization merger plan for Henlius. The offeror received approval from China's National Development and Reform Commission on November 21, 2024, and is in contact with the local authorities of the Ministry of Commerce in China to prepare for the registration with the State Administration of Foreign Exchange. This merger plan will only take effect once all conditions precedent are met and cannot be waived.\nAccording to the announcement on August 23, 2024, the comprehensive documents will be sent within 7 days after the conditions precedent are satisfied or by May 7, 2025, whichever comes first. The offeror, Fosun Pharma, and the company do not guarantee that all conditions precedent will be met, and the merger agreement may not take effect or be completed. Investors should act cautiously and consult professional advisors.\nThe announcement was issued by the board of directors of Fosun Pharma, Henlius, and Fosun Pharma, which includes members Wu Yifang, Guan Xiaohui, and Zhang Wenjie, among others. The board of directors takes responsibility for the accuracy of the announcement and confirms that its content has been carefully considered, with no omissions or misleading information.